Looking Beyond CNS, SK Biopharm Begins First US Oncology Trial
Aims To Double Business This Year
Executive Summary
The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.